Wall Street analysts expect Bristol-Myers Squibb (NYSE:BMY) to announce $11.13 billion in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Bristol-Myers Squibb’s earnings, with estimates ranging from $10.97 billion to $11.35 billion. Bristol-Myers Squibb reported sales of $10.78 billion during the same quarter last year, which indicates a positive year over year growth rate of 3.2%. The firm is scheduled to announce its next quarterly earnings results on Thursday, May 6th.
On average, analysts expect that Bristol-Myers Squibb will report full-year sales of $45.98 billion for the current fiscal year, with estimates ranging from $45.58 billion to $46.26 billion. For the next financial year, analysts forecast that the business will report sales of $47.78 billion, with estimates ranging from $46.76 billion to $48.99 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that that provide coverage for Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Wednesday, February 3rd. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.42 by $0.04. The business had revenue of $11.07 billion for the quarter, compared to the consensus estimate of $10.74 billion. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The firm’s revenue for the quarter was up 39.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.22 earnings per share.
Several equities analysts have recently weighed in on the stock. Societe Generale raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $76.00 price objective on the stock in a research report on Monday, November 16th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised their target price on shares of Bristol-Myers Squibb from $73.00 to $77.00 in a report on Monday, November 30th. The Goldman Sachs Group raised Bristol-Myers Squibb from a “buy” rating to a “conviction-buy” rating in a report on Tuesday, December 15th. TheStreet raised Bristol-Myers Squibb from a “c+” rating to a “b” rating in a report on Monday, December 7th. Finally, Gabelli lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, November 6th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $73.75.
Shares of BMY traded down $0.46 during trading hours on Thursday, hitting $60.53. The company had a trading volume of 474,877 shares, compared to its average volume of 12,958,490. The firm has a market cap of $135.62 billion, a price-to-earnings ratio of -554.40, a PEG ratio of 1.00 and a beta of 0.67. The business has a fifty day moving average of $62.59 and a 200-day moving average of $70.48. Bristol-Myers Squibb has a 12 month low of $45.76 and a 12 month high of $67.16. The company has a quick ratio of 1.58, a current ratio of 1.67 and a debt-to-equity ratio of 0.82.
The business also recently disclosed a quarterly dividend, which was paid on Monday, February 1st. Investors of record on Monday, January 4th were paid a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a dividend yield of 3.24%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.45. The ex-dividend date of this dividend was Thursday, December 31st. Bristol-Myers Squibb’s payout ratio is presently 41.79%.
Institutional investors have recently bought and sold shares of the stock. Fiduciary Planning LLC purchased a new position in Bristol-Myers Squibb during the third quarter worth about $25,000. Retirement Group LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $27,000. Orion Capital Management LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $28,000. Perennial Advisors LLC purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $29,000. Finally, Founders Capital Management purchased a new position in Bristol-Myers Squibb during the 4th quarter valued at $31,000. Institutional investors and hedge funds own 72.41% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Read More: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.